Call for Nominations
Currently Accepting
The Treatment Units for Research on Neurocognition and Schizophrenia (TURNS)
program is currently accepting applications via the Compound Nomination
Form (word
version), (pdf
version) for its second round of nominations of suitable candidate
drugs for enhancing cognition in individuals with schizophrenia.
For more information, see the Call
for Nominations and the Compound
Selection page.
|
TURNS Introduction
The TURNS program
is a National Institute of Mental Health (NIMH) supported network that
will provide an infrastructure for clinical studies of pharmacological
agents for enhancing neurocognition in patients with schizophrenia.
Goals of the TURNS include:
- To establish a clinical research network where clinical studies on
the safety, efficacy, pharmacokinetics and pharmacodymanics of new agents
for the treatment of cognitive deficits of schizophrenia can be investigated.
- To further characterize and define key aspects of cognition in schizophrenia
as potential treatment targets.
- To identify and select promising compounds for studies.
- To define optimal experimental designs to evaluate the efficacy of
primary and augmentation strategies to enhance cognition in schizophrenia
.
- To identify and develop opportunities for industry/academia/government
collaboration in testing compounds of potential utility in alleviating
cognitive deficits in schizophrenia.
- To promote broad adoption and utilization by academia and the pharmaceutical
industry of standardized methods and measures to accelerate testing
and regulatory approval of new compounds targeting cognitive deficits
in schizophrenia.
- To broadly and equitably disseminate state-of-the-art measurement
tools and methodological strategies to evaluate the efficacy of treatments
for cognitive deficits in schizophrenia.
|
